All stories
Science

A pill for pancreatic cancer is hailed as the 'biggest breakthrough in decades'

A pill for pancreatic cancer is hailed as the 'biggest breakthrough in decades'

Pancreatic cancer is one of the deadliest forms of the disease. According to the report, a pill called daraxonrasib has produced promising results in early trials. Of the 61 patients in the study, cancer became undetectable in one in 12, and tumors stopped growing in almost all of them.

The pill targets KRAS mutations, which are found in most pancreatic cancers and drive tumor growth. The article says patients were followed for an average of a year and a half, and in some cases the cancer did not return during that period. One year after starting treatment, 76.6% of patients were alive; among those given chemotherapy alone, that figure is usually around 40-45%.

Doctors say the pill cannot yet be considered a cure, and they do not know how long it can keep the disease at bay. According to the report, tumors stopped growing in 90% of patients in the trial and shrank or disappeared in just over 60%. Still, the five-year survival rate for pancreatic cancer is only about 3% once the disease has spread.

Experts hope a similar effect could be seen in other cancers that carry KRAS mutations. Cancer Research UK chief executive Michelle Mitchell stressed that more research is needed but called it the biggest leap forward for pancreatic cancer patients in decades.